Rapamycin vs metformin: which has the stronger longevity case?
Both are unproven in humans, but they fail differently: rapamycin has a powerful, conflict-free mouse record undercut by a missed human healthspan endpoint, while metformin's best animal data are null and its decisive human trial has never enrolled a single participant.
How they compare
Rapamycin and metformin are the two repurposed prescription drugs most often floated as longevity therapies, and people compare them because both borrow the logic of caloric restriction. Rapamycin inhibits mTOR, metformin activates AMPK, and both pathways overlap with the cellular response to eating less: more autophagy, less growth signaling. Each is cheap, generic, and already taken off-label by people hoping to slow aging.
The key difference the evidence reveals is in the animal data behind them. Rapamycin is the most reproducible life-extending drug in mice, confirmed repeatedly by the NIA even when started late. Metformin alone failed to extend mouse lifespan in the same rigorous program. For both, no completed human trial has measured aging, and metformin carries a randomized signal it may blunt exercise gains.
The table
| Dimension | Rapamycin | Metformin |
|---|---|---|
| What it targets | Inhibits mTORC1, the cell's nutrient sensor, mimicking caloric restriction | Inhibits mitochondrial complex I and activates AMPK, the low-energy sensor |
| Animal evidence | Extends lifespan in mice, replicated across three NIA sites even when started late (grade A) | Metformin alone did not significantly extend mouse lifespan (+7% males, P=0.35; grade D) |
| Human evidence | No trial has measured human mortality; largest healthspan trial missed its primary endpoint | No completed RCT for anti-aging; pivotal TAME trial designed but never enrolled as of 2026 |
| Funding and conflicts | Mouse data government-funded and conflict-free; most-promoted human trial (PEARL) run by a company selling off-label rapamycin | Flagship supportive study reportedly industry-funded (unverified); independent NIH mouse data null; TAME stalled for lack of a commercial sponsor |
| Best understood as | The best-pedigreed mechanism in geroscience, with the human longevity claim untested, not demonstrated | A cheap, plausible blood-sugar drug whose human anti-aging case rests on a trial that has never run |
People also ask
- Is rapamycin or metformin better for longevity?
- Neither is proven in humans. Rapamycin has the stronger case on mechanism: it reliably extends mouse lifespan, conflict-free, while metformin alone was null in the same rigorous mouse program. But no human trial has measured lifespan for either drug.
- Can you take both together?
- The checks do not test combining them, so there is no evidence either way from this material. Both are prescription drugs being self-dosed off-label and unmonitored, and metformin carries a randomized signal it may blunt exercise gains, a real consideration for active people.
- Which one has actual human longevity proof?
- Neither. Rapamycin's human longevity claim is pure mouse-to-human extrapolation, and its biggest healthspan trial missed its primary endpoint. Metformin's decisive TAME trial was designed but never enrolled, stalled for years because aging is not a regulatory indication.
The honest read
Take rapamycin's mouse data seriously and its human marketing skeptically; it is the most credible drug in geroscience on mechanism but unproven in people. Metformin's anti-aging case for non-diabetics is weaker still: null animal data and a decisive trial that never ran.
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.